SequelSEC

Abpro Holdings, Inc. ABPO

Biological Products, (No Diagnostic Substances) · CIK 0001893219 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2024-12-31
Operating income
Unavailable
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Abpro Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Abpro Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-31
RevenueUnavailableUnavailable
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating incomeUnavailableUnavailable
Net incomeUnavailableUnavailable
Research & developmentUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailable
Pretax incomeUnavailableUnavailable
Income tax expenseUnavailableUnavailable
Diluted EPSUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailable
General & administrativeUnavailableUnavailable
Selling & marketingUnavailableUnavailable

Balance

Abpro Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-31
Cash & equivalents$2.85M$723.00K
Total assets$4.66M$3.36M
Current assets$3.78M$2.04M
Total liabilities$19.61M$16.19M
Current liabilities$19.61M$15.74M
Total equity incl. NCI-$14.95M-$88.44M
Temporary (mezzanine) equityUnavailable$75.60M
InventoryUnavailableUnavailable
Accounts receivable$183.00K$88.00K
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$3.94M$7.92M

Cash flow

Abpro Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-31
Operating cash flowUnavailableUnavailable
Capital expendituresUnavailableUnavailable
Investing cash flowUnavailableUnavailable
Financing cash flowUnavailableUnavailable
Net change in cashUnavailableUnavailable
Stock-based compensationUnavailableUnavailable
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

Abpro Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-31
Free cash flowUnavailableUnavailable
Gross marginUnavailableUnavailable
Operating marginUnavailableUnavailable
FCF marginUnavailableUnavailable
SBC / revenueUnavailableUnavailable
Current ratio0.19x0.13x
Revenue YoY growthUnavailableUnavailable
Net marginUnavailableUnavailable
R&D / revenueUnavailableUnavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABPO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO AMGN

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.